Overview
Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma characterized by a T-follicular helper cell (TFH) phenotype and often associated with immune dysregulation and paraneoplastic manifestations 1.Diagnosis
Identification of TFH cell markers such as CD10 expression is crucial 1.
Presence of RHOA mutations correlates with CD10 expression, IDH2 mutations, and TET2 mutations 1.
Bone marrow biopsy often shows involvement in AITL 1.
Flow cytometry and immunohistochemistry are essential for confirming T-cell lineage and specific immunophenotype 1.Management
First-line treatment typically involves multiagent chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) 1.
Rituximab, an anti-CD20 monoclonal antibody, may be added to improve outcomes in some cases 1.
No specific dose adjustments for RHOA mutation status are currently recommended based on available evidence 1.Special Populations
No specific management guidelines differing for pregnancy, pediatrics, or elderly patients are provided in the abstracts 1.
Comorbidities may influence treatment selection but specific recommendations are not detailed in the provided abstracts 1.Key Recommendations
Evaluate for RHOA mutations, which are associated with CD10 expression, IDH2, and TET2 mutations, to inform prognosis and potential treatment strategies (Evidence: Moderate) 1.
Consider multiagent chemotherapy regimens like CHOP as first-line therapy for AITL 1.
Addition of rituximab to chemotherapy may enhance treatment efficacy in AITL patients (Evidence: Moderate) 1.References
1 Nguyen PN, Tran NTB, Nguyen TPX, Ngo TNM, Lai DV, Deel CD et al.. Clinicopathological Implications of RHOA Mutations in Angioimmunoblastic T-Cell Lymphoma: A Meta-analysis: RHOA mutations in AITL. Clinical lymphoma, myeloma & leukemia 2021. link